Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Calistoga Pharmaceuticals

Request full access

Developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases

Seattle, United StatesFounded 2006Biotech & Life Sciences

About Calistoga Pharmaceuticals

Calistoga Pharmaceuticals, Inc. operated as a biopharmaceutical firm with a sharp focus on developing oral medications for cancer and inflammatory diseases by targeting specific isoforms of the phosphoinositide-3 kinase (PI3K) pathway. The company was established in 2006, originating as a spin-out from a drug development program at ICOS Corporation, driven by Frazier Healthcare Ventures. The founding management team included President Dr. Michael Gallatin, a seasoned executive from ICOS with extensive experience in oncology and immunology, and Chief Scientific Officer Dr. Neill Giese. Dr. Gallatin's background includes being a founding scientist at ICOS and work at the Fred Hutchinson Cancer Center, directly influencing Calistoga's direction.

The company's business model centered on the discovery and clinical development of proprietary small-molecule therapeutic candidates. Its primary market was the biopharmaceutical industry, specifically oncology and inflammation therapeutics, with patients suffering from these diseases as the ultimate clients. Revenue generation was tied to the successful progression of its drug candidates through clinical trials, leading to partnerships or acquisition. Calistoga's key achievement was demonstrating the clinical benefit of selectively targeting the delta isoform of PI3K.

Calistoga’s lead product candidate, CAL-101, was a first-in-class oral inhibitor selective for the PI3K delta isoform. This isoform is primarily expressed in white blood cells (leukocytes), making it a precise target for hematological cancers and inflammatory conditions, with the goal of minimizing side effects on other cells. CAL-101 worked through a dual mechanism: it directly induced cancer cell death and also disrupted signals that allowed these cells to survive and proliferate within protective tissue environments. The compound showed promising clinical results in patients with B-cell malignancies like chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. This success and a pipeline of other PI3K inhibitors culminated in the company's acquisition by Gilead Sciences in 2011 for an initial $375 million, with potential for an additional $225 million in milestone payments.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
4
Open positions
None listed
Dealroom signal
66.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Alternative Medicine, Biotechnology, Oncology, Team Collaboration, Inflammatory Diseases, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Feb 2011 $375M $375M Gilead Sciences —
SERIES COther financing Jun 2010 $40M $160M Frazier Healthcare Partners · Latterell Venture Partners · Alta Partners · Three Arch Partners —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Calistoga Pharmaceuticals website traffic

Latest recorded traffic for Calistoga Pharmaceuticals is 0 monthly website visits. Calistoga Pharmaceuticals's team declined 33.3% over the past year.

Latest monthly visits0 1-year team growth-33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Calistoga Pharmaceuticals in the Seattle ecosystem

Live from Dealroom

The Calistoga Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Frazier Healthcare Partners
  • Alta Partners
  • Three Arch Partners
  • Amgen Ventures

Series B and later1 investor entered at this stage

  • Latterell Venture Partners

Other known investors1 additional known investor

  • Gilead Sciences
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Seattle HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Calistoga Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Calistoga Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.